Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Karl Ulrich Bayer

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-PHARM General Operations
Phone303/724-3610

    Collapse Research 
    Collapse research activities and funding
    U01NS094261     (BAYER, K. ULRICH)Mar 1, 2017 - Feb 29, 2020
    NIH
    A strategy for pharmacological treatment of global cerebral ischemia
    Role: Principal Investigator
    R21NS095760     (BAYER, K. ULRICH)Sep 1, 2016 - Aug 31, 2018
    NIH
    Restoring synaptic function in Down Syndrome mice
    Role: Principal Investigator
    R21DA036300     (BAYER, K. ULRICH)Aug 1, 2013 - Jul 31, 2015
    NIH
    Persistent reversal of addiction behavior by a transient treatment
    Role: Principal Investigator
    R01NS081248     (BAYER, K. ULRICH)Jul 1, 2013 - Mar 31, 2021
    NIH
    CaMKII autophosphorylation in opposing directions of synaptic plasticity
    Role: Principal Investigator
    R01NS080851     (HERSON, PACO S)May 1, 2013 - Apr 30, 2019
    NIH
    CaMKII in global cerebral ischemia
    Role: Co-Investigator
    R01NS052644     (BAYER, K. ULRICH)Jan 30, 2007 - Nov 30, 2012
    NIH
    Structural and Catalytic Functions of CaMKII in Neurons
    Role: Principal Investigator
    R21DK070735     (BAYER, K. ULRICH)Feb 1, 2006 - Jan 31, 2009
    NIH
    CaMKII signaling in insulin secretion and response
    Role: Principal Investigator
    R03NS050120     (BAYER, K. ULRICH)Jul 15, 2005 - Jun 30, 2007
    NIH
    Cell-permeable inibitors specific for CaMKII
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Tullis JE, Larsen ME, Rumian NL, Freund RK, Boxer EE, Brown CN, Coultrap SJ, Schulman H, Aoto J, Dell'Acqua ML, Bayer KU. LTP induction by structural rather than enzymatic functions of CaMKII. Nature. 2023 Sep; 621(7977):146-153. PMID: 37648853.
      View in: PubMed
    2. Rumian NL, Freund RK, Dell'Acqua ML, Coultrap SJ, Bayer KU. Decreased nitrosylation of CaMKII causes aging-associated impairments in memory and synaptic plasticity in mice. Sci Signal. 2023 07 25; 16(795):eade5892. PMID: 37490545.
      View in: PubMed
    3. Tullis JE, Bayer KU. Distinct synaptic pools of DAPK1 differentially regulate activity-dependent synaptic CaMKII accumulation. iScience. 2023 May 19; 26(5):106723. PMID: 37216104.
      View in: PubMed
    4. Larsen ME, Buonarati OR, Qian H, Hell JW, Bayer KU. Stimulating ?-adrenergic receptors promotes synaptic potentiation by switching CaMKII movement from LTD to LTP mode. J Biol Chem. 2023 06; 299(6):104706. PMID: 37061000.
      View in: PubMed
    5. Rumian NL, Brown CN, Hendry-Hofer TB, Rossetti T, Orfila JE, Tullis JE, Dwoskin LP, Buonarati OR, Lisman JE, Quillinan N, Herson PS, Bebarta VS, Bayer KU. Short-term CaMKII inhibition with tatCN19o does not erase pre-formed memory in mice and is neuroprotective in pigs. J Biol Chem. 2023 05; 299(5):104693. PMID: 37037305.
      View in: PubMed
    6. Rumian NL, Brown CN, Hendry-Hofer TB, Rossetti T, Orfila JE, Tullis JE, Dwoskin LP, Buonarati OR, Lisman JE, Quillinan N, Herson PS, Bebarta VS, Bayer KU. Short-term CaMKII inhibition with tatCN19o does not erase pre-formed memory and is neuroprotective in non-rodents. bioRxiv. 2023 Jan 23. PMID: 36747773.
      View in: PubMed
    7. Ramirez-Gordillo D, Bayer KU, Restrepo D. Hippocampal-prefrontal theta coupling develops as mice become proficient in associative odorant discrimination learning. eNeuro. 2022 Sep 20. PMID: 36127136.
      View in: PubMed
    8. Cook SG, Rumian NL, Bayer KU. CaMKII T286 phosphorylation has distinct essential functions in three forms of long-term plasticity. J Biol Chem. 2022 09; 298(9):102299. PMID: 35872016.
      View in: PubMed
    9. Brown CN, Rumian NL, Tullis JE, Coultrap SJ, Bayer KU. A?-induced synaptic impairments require CaMKII activity that is stimulated by indirect signaling events. iScience. 2022 Jun 17; 25(6):104368. PMID: 35620430.
      View in: PubMed
    10. Buonarati OR, Miller AP, Coultrap SJ, Bayer KU, Reichow SL. Conserved and divergent features of neuronal CaMKII holoenzyme structure, function, and high-order assembly. Cell Rep. 2021 12 28; 37(13):110168. PMID: 34965414.
      View in: PubMed
    11. Rumian NL, Chalmers NE, Tullis JE, Herson PS, Bayer KU. CaMKIIa knockout protects from ischemic neuronal cell death after resuscitation from cardiac arrest. Brain Res. 2021 12 15; 1773:147699. PMID: 34687697.
      View in: PubMed
    12. Tullis JE, Buonarati OR, Coultrap SJ, Bourke AM, Tiemeier EL, Kennedy MJ, Herson PS, Bayer KU. GluN2B S1303 phosphorylation by CaMKII or DAPK1: no indication for involvement in ischemia or LTP. iScience. 2021 Oct 22; 24(10):103214. PMID: 34704002.
      View in: PubMed
    13. Brown CN, Cook SG, Allen HF, Crosby KC, Singh T, Coultrap SJ, Bayer KU. Characterization of six CaMKIIa variants found in patients with schizophrenia. iScience. 2021 Oct 22; 24(10):103184. PMID: 34667946.
      View in: PubMed
    14. Goodell DJ, Tullis JE, Bayer KU. Young DAPK1 knockout mice have altered presynaptic function. J Neurophysiol. 2021 05 01; 125(5):1973-1981. PMID: 33881939.
      View in: PubMed
    15. Cook SG, Buonarati OR, Coultrap SJ, Bayer KU. CaMKII holoenzyme mechanisms that govern the LTP versus LTD decision. Sci Adv. 2021 04; 7(16). PMID: 33853773.
      View in: PubMed
    16. Tullis JE, Rumian NL, Brown CN, Bayer KU. The CaMKII K42M and K42R mutations are equivalent in suppressing kinase activity and targeting. PLoS One. 2020; 15(7):e0236478. PMID: 32716967.
      View in: PubMed
    17. Buonarati OR, Cook SG, Goodell DJ, Chalmers NE, Rumian NL, Tullis JE, Restrepo S, Coultrap SJ, Quillinan N, Herson PS, Bayer KU. CaMKII versus DAPK1 Binding to GluN2B in Ischemic Neuronal Cell Death after Resuscitation from Cardiac Arrest. Cell Rep. 2020 01 07; 30(1):1-8.e4. PMID: 31914378.
      View in: PubMed
    18. Chalmers NE, Yonchek J, Steklac KE, Ramsey M, Bayer KU, Herson PS, Quillinan N. Calcium/Calmodulin-Dependent Kinase (CaMKII) Inhibition Protects Against Purkinje Cell Damage Following CA/CPR in Mice. Mol Neurobiol. 2020 Jan; 57(1):150-158. PMID: 31520314.
      View in: PubMed
    19. Bayer KU, Schulman H. CaM Kinase: Still Inspiring at 40. Neuron. 2019 08 07; 103(3):380-394. PMID: 31394063.
      View in: PubMed
    20. Cook SG, Goodell DJ, Restrepo S, Arnold DB, Bayer KU. Simultaneous Live Imaging of Multiple Endogenous Proteins Reveals a Mechanism for Alzheimer's-Related Plasticity Impairment. Cell Rep. 2019 04 16; 27(3):658-665.e4. PMID: 30995464.
      View in: PubMed
    21. Opazo P, Viana da Silva S, Carta M, Breillat C, Coultrap SJ, Grillo-Bosch D, Sainlos M, Coussen F, Bayer KU, Mulle C, Choquet D. CaMKII Metaplasticity Drives A? Oligomer-Mediated Synaptotoxicity. Cell Rep. 2018 06 12; 23(11):3137-3145. PMID: 29898386.
      View in: PubMed
    22. Myers JB, Zaegel V, Coultrap SJ, Miller AP, Bayer KU, Reichow SL. Publisher Correction: The CaMKII holoenzyme structure in activation-competent conformations. Nat Commun. 2018 05 25; 9:16180. PMID: 29799013.
      View in: PubMed
    23. Cook SG, Bourke AM, O'Leary H, Zaegel V, Lasda E, Mize-Berge J, Quillinan N, Tucker CL, Coultrap SJ, Herson PS, Bayer KU. Analysis of the CaMKIIa and ? splice-variant distribution among brain regions reveals isoform-specific differences in holoenzyme formation. Sci Rep. 2018 04 03; 8(1):5448. PMID: 29615706.
      View in: PubMed
    24. Woolfrey KM, O'Leary H, Goodell DJ, Robertson HR, Horne EA, Coultrap SJ, Dell'Acqua ML, Bayer KU. CaMKII regulates the depalmitoylation and synaptic removal of the scaffold protein AKAP79/150 to mediate structural long-term depression. J Biol Chem. 2018 02 02; 293(5):1551-1567. PMID: 29196604.
      View in: PubMed
    25. Goodell DJ, Zaegel V, Coultrap SJ, Hell JW, Bayer KU. DAPK1 Mediates LTD by Making CaMKII/GluN2B Binding LTP Specific. Cell Rep. 2017 06 13; 19(11):2231-2243. PMID: 28614711.
      View in: PubMed
    26. Myers JB, Zaegel V, Coultrap SJ, Miller AP, Bayer KU, Reichow SL. The CaMKII holoenzyme structure in activation-competent conformations. Nat Commun. 2017 06 07; 8:15742. PMID: 28589927.
      View in: PubMed
    27. Deng G, Orfila JE, Dietz RM, Moreno-Garcia M, Rodgers KM, Coultrap SJ, Quillinan N, Traystman RJ, Bayer KU, Herson PS. Autonomous CaMKII Activity as a Drug Target for Histological and Functional Neuroprotection after Resuscitation from Cardiac Arrest. Cell Rep. 2017 01 31; 18(5):1109-1117. PMID: 28147268.
      View in: PubMed
    28. Dosemeci A, Toy D, Burch A, Bayer KU, Tao-Cheng JH. CaMKII-mediated displacement of AIDA-1 out of the postsynaptic density core. FEBS Lett. 2016 09; 590(17):2934-9. PMID: 27477489.
      View in: PubMed
    29. Goodell DJ, Benke TA, Bayer KU. Developmental restoration of LTP deficits in heterozygous CaMKIIa KO mice. J Neurophysiol. 2016 11 01; 116(5):2140-2151. PMID: 27535377.
      View in: PubMed
    30. Khan S, Conte I, Carter T, Bayer KU, Molloy JE. Multiple CaMKII Binding Modes to the Actin Cytoskeleton Revealed by Single-Molecule Imaging. Biophys J. 2016 Jul 26; 111(2):395-408. PMID: 27463141.
      View in: PubMed
    31. Barcomb K, Hell JW, Benke TA, Bayer KU. The CaMKII/GluN2B Protein Interaction Maintains Synaptic Strength. J Biol Chem. 2016 07 29; 291(31):16082-9. PMID: 27246855.
      View in: PubMed
    32. Barcomb K, Goodell DJ, Arnold DB, Bayer KU. Live imaging of endogenous Ca??/calmodulin-dependent protein kinase II in neurons reveals that ischemia-related aggregation does not require kinase activity. J Neurochem. 2015 Nov; 135(4):666-73. PMID: 26212614.
      View in: PubMed
    33. Coultrap SJ, Zaegel V, Bayer KU. CaMKII isoforms differ in their specific requirements for regulation by nitric oxide. FEBS Lett. 2014 Dec 20; 588(24):4672-6. PMID: 25447522.
      View in: PubMed
    34. Tao-Cheng JH, Yang Y, Bayer KU, Reese TS, Dosemeci A. NMDA-induced accumulation of Shank at the postsynaptic density is mediated by CaMKII. Biochem Biophys Res Commun. 2014 Jul 18; 450(1):808-11. PMID: 24952157.
      View in: PubMed
    35. Thein S, Pham A, Bayer KU, Tao-Cheng JH, Dosemeci A. IKK regulates the deubiquitinase CYLD at the postsynaptic density. Biochem Biophys Res Commun. 2014 Jul 18; 450(1):550-4. PMID: 24928390.
      View in: PubMed
    36. Coultrap SJ, Bayer KU. Nitric oxide induces Ca2+-independent activity of the Ca2+/calmodulin-dependent protein kinase II (CaMKII). J Biol Chem. 2014 Jul 11; 289(28):19458-65. PMID: 24855644.
      View in: PubMed
    37. Barcomb K, Buard I, Coultrap SJ, Kulbe JR, O'Leary H, Benke TA, Bayer KU. Autonomous CaMKII requires further stimulation by Ca2+/calmodulin for enhancing synaptic strength. FASEB J. 2014 Aug; 28(8):3810-9. PMID: 24843070.
      View in: PubMed
    38. Goodell DJ, Eliseeva TA, Coultrap SJ, Bayer KU. CaMKII binding to GluN2B is differentially affected by macromolecular crowding reagents. PLoS One. 2014; 9(5):e96522. PMID: 24796865.
      View in: PubMed
    39. Bernard PB, Castano AM, Bayer KU, Benke TA. Necessary, but not sufficient: insights into the mechanisms of mGluR mediated long-term depression from a rat model of early life seizures. Neuropharmacology. 2014 Sep; 84:1-12. PMID: 24780380.
      View in: PubMed
    40. Turecek J, Yuen GS, Han VZ, Zeng XH, Bayer KU, Welsh JP. NMDA receptor activation strengthens weak electrical coupling in mammalian brain. Neuron. 2014 Mar 19; 81(6):1375-1388. PMID: 24656255.
      View in: PubMed
    41. Thein S, Tao-Cheng JH, Li Y, Bayer KU, Reese TS, Dosemeci A. CaMKII mediates recruitment and activation of the deubiquitinase CYLD at the postsynaptic density. PLoS One. 2014; 9(3):e91312. PMID: 24614225.
      View in: PubMed
    42. Coultrap SJ, Freund RK, O'Leary H, Sanderson JL, Roche KW, Dell'Acqua ML, Bayer KU. Autonomous CaMKII mediates both LTP and LTD using a mechanism for differential substrate site selection. Cell Rep. 2014 Feb 13; 6(3):431-7. PMID: 24485660.
      View in: PubMed
    43. Kulbe JR, Mulcahy Levy JM, Coultrap SJ, Thorburn A, Bayer KU. Excitotoxic glutamate insults block autophagic flux in hippocampal neurons. Brain Res. 2014 Jan 13; 1542:12-9. PMID: 24505621.
      View in: PubMed
    44. Liu X, Liu Y, Zhong P, Wilkinson B, Qi J, Olsen CM, Bayer KU, Liu QS. CaMKII activity in the ventral tegmental area gates cocaine-induced synaptic plasticity in the nucleus accumbens. Neuropsychopharmacology. 2014 Mar; 39(4):989-99. PMID: 24154664.
      View in: PubMed
    45. Barcomb K, Coultrap SJ, Bayer KU. Enzymatic activity of CaMKII is not required for its interaction with the glutamate receptor subunit GluN2B. Mol Pharmacol. 2013 Dec; 84(6):834-43. PMID: 24056996.
      View in: PubMed
    46. Yang Y, Tao-Cheng JH, Bayer KU, Reese TS, Dosemeci A. Camkii-mediated phosphorylation regulates distributions of Syngap-a1 and -a2 at the postsynaptic density. PLoS One. 2013; 8(8):e71795. PMID: 23967245.
      View in: PubMed
    47. Tao-Cheng JH, Yang Y, Bayer KU, Reese TS, Dosemeci A. Effects of CaMKII inhibitor tatCN21 on activity-dependent redistribution of CaMKII in hippocampal neurons. Neuroscience. 2013 Aug 06; 244:188-96. PMID: 23583761.
      View in: PubMed
    48. Loweth JA, Li D, Cortright JJ, Wilke G, Jeyifous O, Neve RL, Bayer KU, Vezina P. Persistent reversal of enhanced amphetamine intake by transient CaMKII inhibition. J Neurosci. 2013 Jan 23; 33(4):1411-6. PMID: 23345217.
      View in: PubMed
    49. Boguslavsky S, Chiu T, Foley KP, Osorio-Fuentealba C, Antonescu CN, Bayer KU, Bilan PJ, Klip A. Myo1c binding to submembrane actin mediates insulin-induced tethering of GLUT4 vesicles. Mol Biol Cell. 2012 Oct; 23(20):4065-78. PMID: 22918957.
      View in: PubMed
    50. Coultrap SJ, Bayer KU. CaMKII regulation in information processing and storage. Trends Neurosci. 2012 Oct; 35(10):607-18. PMID: 22717267.
      View in: PubMed
    51. Coultrap SJ, Barcomb K, Bayer KU. A significant but rather mild contribution of T286 autophosphorylation to Ca2+/CaM-stimulated CaMKII activity. PLoS One. 2012; 7(5):e37176. PMID: 22615928.
      View in: PubMed
    52. Coultrap SJ, Bayer KU. Improving a natural CaMKII inhibitor by random and rational design. PLoS One. 2011; 6(10):e25245. PMID: 21984908.
      View in: PubMed
    53. O'Leary H, Liu WH, Rorabaugh JM, Coultrap SJ, Bayer KU. Nucleotides and phosphorylation bi-directionally modulate Ca2+/calmodulin-dependent protein kinase II (CaMKII) binding to the N-methyl-D-aspartate (NMDA) receptor subunit GluN2B. J Biol Chem. 2011 Sep 09; 286(36):31272-81. PMID: 21768120.
      View in: PubMed
    54. Sanhueza M, Fernandez-Villalobos G, Stein IS, Kasumova G, Zhang P, Bayer KU, Otmakhov N, Hell JW, Lisman J. Role of the CaMKII/NMDA receptor complex in the maintenance of synaptic strength. J Neurosci. 2011 Jun 22; 31(25):9170-8. PMID: 21697368.
      View in: PubMed
    55. Coultrap SJ, Vest RS, Ashpole NM, Hudmon A, Bayer KU. CaMKII in cerebral ischemia. Acta Pharmacol Sin. 2011 Jul; 32(7):861-72. PMID: 21685929.
      View in: PubMed
    56. Marsden KC, Shemesh A, Bayer KU, Carroll RC. Selective translocation of Ca2+/calmodulin protein kinase IIalpha (CaMKIIalpha) to inhibitory synapses. Proc Natl Acad Sci U S A. 2010 Nov 23; 107(47):20559-64. PMID: 21059908.
      View in: PubMed
    57. Buard I, Coultrap SJ, Freund RK, Lee YS, Dell'Acqua ML, Silva AJ, Bayer KU. CaMKII "autonomy" is required for initiating but not for maintaining neuronal long-term information storage. J Neurosci. 2010 Jun 16; 30(24):8214-20. PMID: 20554872.
      View in: PubMed
    58. Vest RS, O'Leary H, Coultrap SJ, Kindy MS, Bayer KU. Effective post-insult neuroprotection by a novel Ca(2+)/ calmodulin-dependent protein kinase II (CaMKII) inhibitor. J Biol Chem. 2010 Jul 02; 285(27):20675-82. PMID: 20424167.
      View in: PubMed
    59. Cipolletta E, Monaco S, Maione AS, Vitiello L, Campiglia P, Pastore L, Franchini C, Novellino E, Limongelli V, Bayer KU, Means AR, Rossi G, Trimarco B, Iaccarino G, Illario M. Calmodulin-dependent kinase II mediates vascular smooth muscle cell proliferation and is potentiated by extracellular signal regulated kinase. Endocrinology. 2010 Jun; 151(6):2747-59. PMID: 20392834.
      View in: PubMed
    60. Coultrap SJ, Buard I, Kulbe JR, Dell'Acqua ML, Bayer KU. CaMKII autonomy is substrate-dependent and further stimulated by Ca2+/calmodulin. J Biol Chem. 2010 Jun 04; 285(23):17930-7. PMID: 20353941.
      View in: PubMed
    61. Vest RS, O'Leary H, Bayer KU. Differential regulation by ATP versus ADP further links CaMKII aggregation to ischemic conditions. FEBS Lett. 2009 Nov 19; 583(22):3577-81. PMID: 19840793.
      View in: PubMed
    62. Vest RS, Davies KD, O'Leary H, Port JD, Bayer KU. Dual mechanism of a natural CaMKII inhibitor. Mol Biol Cell. 2007 Dec; 18(12):5024-33. PMID: 17942605.
      View in: PubMed
    63. Rokhlin OW, Taghiyev AF, Bayer KU, Bumcrot D, Koteliansk VE, Glover RA, Cohen MB. Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival. Cancer Biol Ther. 2007 May; 6(5):732-42. PMID: 17387273.
      View in: PubMed
    64. O'Leary H, Lasda E, Bayer KU. CaMKIIbeta association with the actin cytoskeleton is regulated by alternative splicing. Mol Biol Cell. 2006 Nov; 17(11):4656-65. PMID: 16928958.
      View in: PubMed
    65. O'Leary H, Sui X, Lin PJ, Volpe P, Bayer KU. Nuclear targeting of the CaMKII anchoring protein alphaKAP is regulated by alternative splicing and protein kinases. Brain Res. 2006 May 01; 1086(1):17-26. PMID: 16616897.
      View in: PubMed
    66. Bayer KU, LeBel E, McDonald GL, O'Leary H, Schulman H, De Koninck P. Transition from reversible to persistent binding of CaMKII to postsynaptic sites and NR2B. J Neurosci. 2006 Jan 25; 26(4):1164-74. PMID: 16436603.
      View in: PubMed
    67. Illario M, Cavallo AL, Bayer KU, Di Matola T, Fenzi G, Rossi G, Vitale M. Calcium/calmodulin-dependent protein kinase II binds to Raf-1 and modulates integrin-stimulated ERK activation. J Biol Chem. 2003 Nov 14; 278(46):45101-8. PMID: 12954639.
      View in: PubMed
    68. Fink CC, Bayer KU, Myers JW, Ferrell JE, Schulman H, Meyer T. Selective regulation of neurite extension and synapse formation by the beta but not the alpha isoform of CaMKII. Neuron. 2003 Jul 17; 39(2):283-97. PMID: 12873385.
      View in: PubMed
    69. Nori A, Lin PJ, Cassetti A, Villa A, Bayer KU, Volpe P. Targeting of alpha-kinase-anchoring protein (alpha KAP) to sarcoplasmic reticulum and nuclei of skeletal muscle. Biochem J. 2003 Mar 15; 370(Pt 3):873-80. PMID: 12470297.
      View in: PubMed
    70. Bayer KU, De Koninck P, Schulman H. Alternative splicing modulates the frequency-dependent response of CaMKII to Ca(2+) oscillations. EMBO J. 2002 Jul 15; 21(14):3590-7. PMID: 12110572.
      View in: PubMed
    71. Bayer KU, Schulman H. Regulation of signal transduction by protein targeting: the case for CaMKII. Biochem Biophys Res Commun. 2001 Dec 21; 289(5):917-23. PMID: 11741277.
      View in: PubMed
    72. Bayer KU, De Koninck P, Leonard AS, Hell JW, Schulman H. Interaction with the NMDA receptor locks CaMKII in an active conformation. Nature. 2001 Jun 14; 411(6839):801-5. PMID: 11459059.
      View in: PubMed
    73. Bayer KU, L?hler J, Schulman H, Harbers K. Developmental expression of the CaM kinase II isoforms: ubiquitous gamma- and delta-CaM kinase II are the early isoforms and most abundant in the developing nervous system. Brain Res Mol Brain Res. 1999 Jun 18; 70(1):147-54. PMID: 10381553.
      View in: PubMed
    74. Bayer KU, Harbers K, Schulman H. alphaKAP is an anchoring protein for a novel CaM kinase II isoform in skeletal muscle. EMBO J. 1998 Oct 01; 17(19):5598-605. PMID: 9755160.
      View in: PubMed
    75. Bayer KU, L?hler J, Harbers K. An alternative, nonkinase product of the brain-specifically expressed Ca2+/calmodulin-dependent kinase II alpha isoform gene in skeletal muscle. Mol Cell Biol. 1996 Jan; 16(1):29-36. PMID: 8524307.
      View in: PubMed
    Bayer's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (306) concept(s)
    _
    Co-Authors Expand Description
    See all (19) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)